Linked Life Data

17330401

Source:http://linkedlifedata.com/resource/pubmed/id/17330401

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-3-2
pubmed:abstractText
Distinct immune responses are required for efficient elimination of different pathogens. Programming of the desired type of immune response by safe non-replicating vaccines requires suitable vaccine adjuvants that determine the magnitude and quality of immune responses elicited. Unfortunately, rational vaccine design with a logical choice of adjuvants is hampered by a lack of knowledge about the mechanism(s) of adjuvant activity. Synthetic natural and non-natural oligodeoxynucleotides containing specific motifs centered on a CpG dinucleotide are potent immunostimulatory agents through their binding to toll-like receptor 9 (TLR9). The evolutionary conservation of TLR9 function and the broad therapeutic potential of CpG oligodeoxynucleotides make them of considerable interest for use in human and veterinary medicine. Recent advances in the development and utility of TLR9 agonists in prophylactic or therapeutic vaccines against infectious diseases are focused on.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1464-8431
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
45-52
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
pubmed:affiliation
Swiss Tropical Institute, Department of Medical Parasitology and Infection Biology, Socinstrasse 57, 4002 Basel, Switzerland. Claudia.Daubenberger@unibas.ch
pubmed:publicationType
Journal Article, Review